TSCAN THERAPEUTICS INC. - COMMON STOCK

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

28 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

26 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

14 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

06 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

29 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

18 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

04 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

09 Dec 2023 12:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations

07 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition

04 Dec 2023 16:05:00 By Nasdaq GlobeNewswire

TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer

04 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years

30 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

09 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting

06 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition

02 Nov 2023 09:05:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting

27 Sep 2023 09:06:51 By Nasdaq GlobeNewswire

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME

29 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

10 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Transition of Chief Financial Officer

29 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors

06 Jun 2023 07:00:00 By Nasdaq GlobeNewswire